Post by Grünenthal Group

We have taken an important step to strengthen our capabilities in genetic medicine and #oligonucleotide development by joining CNATM - Cluster for Nucleic Acid Therapeutics Munich​. The CNATM brings together leading academic groups, research institutions, biotech companies and industry partners in one of Germany’s most exciting nucleic acid therapeutics innovation ecosystems. Our shared goal is to connect cutting-edge science, biotech innovation and patient-focused drug discovery to help accelerate next-generation nucleic acid therapeutics towards medicines that can make a meaningful difference for patients. We look forward to working with the German and international nucleic acid therapeutics community to drive innovation in this rapidly evolving field. Learn more about our capabilities and the CNATM in our press release: https://bit.ly/4w288Tv Thomas Carell & Stefan Engelhardt #WeAreGrünenthal #GeneticMedicine #Research #Collaboration